FASTEST
rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time

OBJECTIVE: To evaluate the safety and efficacy of recombinant factor VIIa (rFVIIa) compared to placebo in treating acute intracerebral hemorrhage (ICH)

STUDY DESIGN: International, multicenter, prospective, randomized, double-blind controlled trial, N=626

CONCLUSIONS: rFVIIa slowed growth of hematoma when administered within 2 hours of ICH symptom onset in patients with a spot sign but had slightly increased risk for life-threatening thromboembolic complications and did not improve overall functional outcomes when compared to placebo.

American Heart Association.